AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Sep - KIMS to attend J.P. Morgan India Conference group meeting in Mumbai on September 21, 2026.
Source: Bse
Krishna Institute of Medical Sciences Limited (KIMS)
Large CapPharma stocks · Large cap · NSE
Krishna Institute of Medical Sciences Limited (KIMS) is a multi-specialty healthcare provider operating across Telangana, Andhra Pradesh, Maharashtra, Karnataka, and Kerala. The company focuses on delivering affordable, quality care with patient-centric systems, advanced medical technology, and clinical outcome-driven excellence.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals15 Oct 2026 · screener
Latest result04 Aug, 12:03 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
60BullishSMA20 -5.7% / mo · RSI oversold · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 33
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
KIMSD candles · FIT view-0.1%Latest close ₹674.10 on 2026-10-21
Bar
-1.0%
RSI
28
MACD hist
-3.49
52W pos
35%
2026-10-21O ₹680.95H ₹683.00L ₹661.30C ₹674.10Vol 3.8L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
KIMSNifty PharmaNifty 500
- KIMS
- -14.7%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -8.2 pp
Chart stats
21 Oct 2026- From 52W high
- -21.4%
- 52W range position
- 35%
- ATR (14)
- 3.3%
- Volume vs 20D
- 0.72x
- Avg traded value
- ₹37.9 Cr
- 20D price channel
- ₹661.3 - ₹811.2
₹858
₹575.8 - ₹858
₹22.2
Latest completed session
20-session average
25.2% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management trust is acceptable, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED21
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad2
Revenue +35.3% · PAT -56.5% YoY
Technical
Bullish60
Price trend and sector-relative-strength timing.
Valuation
Legacy model-1122.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Healthy Trust70
medium confidence · 3/3 claims checked
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 2/100PAT -56% YoY · margin compression · Rev +35% YoY · +10% QoQ
Filed 03 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,180 Cr | +35.3% | +9.8% |
| EBITDA | ₹223 Cr | +15.5% | +8.3% |
| Operating margin | 19.0% | -300 bps | +0 bps |
| PAT | ₹37 Cr | -56.5% | +12.1% |
| PAT margin | 3.1% | -661 bps | +7 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 140.00
- P/B
- 12.33
- EV/EBITDA
- 28.66
- Market Cap
- 29104.00Cr
Profitability
- ROE
- 11.30%
- ROCE
- 9.50%
- ROA
- 2.52%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 24.00%
- EPS 5Y
- 4.00%
- Revenue 3Y
- 21.00%
- EPS 3Y
- -9.00%
Balance Sheet
- Debt/Equity
- 1.89
- Interest Coverage
- 3.29×
- Altman Z
- 4.61
- Book Value
- 56.20
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 6/5
- OCF
- 511.00 Cr
- EPS TTM
- 5.05
Shareholding
- Promoter Hold
- 32.49%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 41%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 1,180+9.8% vs prev
Net Profit
₹ CrLatest: 37.0+12.1% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 28. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~6.1% over last month) — short-term momentum negative.
- RSI(14) at 28 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- 21% off 52W high · 17% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
55
RS percentile
Stage 1 Base / Transition
1M return
-14.5%
3M return
-14.7%
6M return
+2.9%
1Y return
-8.3%
RS 1D
+1
RS 20D
-12
Sector rank
#2
Industry rank
#10
Stage evidence
- Price is 9.9% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed +0.6% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
weakening
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 100.13+0.28%
RS vs Nifty 500100
Valuation & peers
U-Score 21 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 21 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth10/25
Quality1/20
Balance Sheet1/15
Cash Flow4/10
Piotroski
7/9 (+5)
Penalties
0
Raw sum
21
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
21/100 · legacy band OVERVALUED
Positive drivers
- Piotroski is strong at 7/9.
- Growth contributes 10/25 to the score.
- Cash flow contributes 4/10 to the score.
Main drags
- Fair-value margin of safety is negative at -1122.4%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Quality is weaker at 1/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
140.0
PB
12.3
EV/EBITDA
28.7
ROE
11.3%
ROCE
9.5%
FCF Yield
—
Debt/Equity
1.9
MoS
-1122.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
21
Previous: 21
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-1122.4%
Previous: -1130.4%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
21
21
21
21
21
21
21
21
21
21
21
21
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹79.91
-743.6% MoS
Growth-justified P/E
10.9
Growth-justified Value
₹55.15
-1122.4% MoS
PEG
35.00
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MEDANTA
Large
Global Health Limited
Healthcare Services
match 164
45
60.1
15.2%
-33%
WATCHLIST
NH
Small
Narayana Hrudayalaya Ltd.
Healthcare Services
match 158
49
40.8
20.5%
+3%
FAIR VALUE
AGARWALEYE
Micro
Dr. Agarwal's Health Care Limited
Healthcare Services
match 156
30
99.3
6.0%
-122%
OVERVALUED
HCG
Micro
Healthcare Global Enterprises Limited
Healthcare Services
match 154
28
182.0
2.5%
-727%
OVERVALUED
PARKHOSPS
Micro
Park Medi World Limited
Healthcare Services
match 154
44
37.2
16.8%
+22%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis under stressReviewed 2026-10-13T07:46:16.869Z
Management commentary snapshot
KIMS reports strong Q1 FY27 revenue growth of 36.1% YoY, driven by capacity expansion and patient volumes, but profitability significantly declines with PAT down 56.0% YoY and EBITDA margin contracting to 20.1%.
While KIMS continues its aggressive expansion, reflected in robust revenue and patient volume growth, the significant decline in PBT and PAT, coupled with margin compression, raises concerns about the profitability of new capacity. The ramp-up of several new units, some still EBITDA negative, is weighing on overall financial performance, putting the growth-at-all-costs thesis under stress.
Growth engines
Strategic Expansion & Capacity Additions
The company is adding 1300+ beds through greenfield, acquisitions, and O&M opportunities, reflecting a sustained expansion strategy.
Strategic Doctor Partnerships
Building long-term alignment through equity participation fosters ownership, retention, and clinical excellence.
Advanced Medical Technology
Investment in technologies like the 4-Arm HD da Vinci Robotic Surgical System, MrGFUS Focussed Ultrasound, and Mako Robotic for Knee Replacement drives high-value clinical services.
Regional Market Leadership
Focused expansion aims to establish a dominant presence in target geographies and accelerate new business growth.
Capacity and execution
Kondapur Bed Addition
787 beds were added in Kondapur in Q1 FY27, contributing to the overall bed capacity increase.
Palakkad Bed Addition
208 beds were added in Palakkad in Q1 FY27, with the unit successfully commissioned and operationalized in April 2026.
Overall Bed Capacity
Total bed capacity increased to 7,459 in Q1 FY27 from 6,464 in Q4 FY26.
Tailwinds
Successful Acquisition Turnaround
Recent acquisitions have successfully turned around EBITDA from single-digit to double-digit percentages post-integration.
Growing Patient Preference
KIMS UAIMS Hospital (Sangli) has witnessed a positive shift in consumer preference, enhancing patient access and referral networks.
Ramping Up New Units to Profitability
Palakkad, Thane, and Guntur units became EBITDA positive in Q1 FY27, indicating progress in new unit stabilization.
Headwinds
Profitability Decline
PBT and PAT declined by 50.2% and 56.0% YoY respectively, despite strong revenue growth, indicating pressure on the bottom line.
EBITDA Margin Contraction
Overall EBITDA margin decreased to 20.1% in Q1 FY27 from 22.7% in Q1 FY26, suggesting higher operational costs or lower realization from new capacity.
Lower Occupancy Rate
Occupancy rate declined to 49.0% in Q1 FY27 from 51.3% in Q1 FY26, likely due to the significant increase in operational beds.
Negative EBITDA from New Units
Karnataka units (Mahadevapura, Electronic City) and Kompally unit reported negative EBITDA in Q1 FY27, impacting overall group profitability.
Risk radar
Integration and Ramp-up of New Capacity
The rapid addition of beds and new units poses risks related to achieving optimal occupancy and profitability, as seen with current margin compression and negative EBITDA from some new units.
Sustaining Profitability Amidst Expansion
Despite revenue growth, the significant YoY decline in PBT and PAT suggests challenges in maintaining profitability margins during aggressive expansion.
Competition in New Geographies
Expanding into new regions like Karnataka and Kerala may face intense competition, impacting occupancy rates and ARPOB in those clusters.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
YoY comparison is crucial to assess the impact of significant capacity additions and overall growth trajectory. QoQ comparison is important to monitor sequential momentum, utilization ramp-up, and the operational efficiency of newly commissioned and integrating units.
Sector KPIs management disclosed
Operating Revenue
Operating Revenue for Q1 FY27 was 11,795 Million, up 35.3% YoY and 9.8% QoQ.
EBITDA
EBITDA for Q1 FY27 was 2,398 Million, up 20.1% YoY and 10.9% QoQ.
EBITDA Margin
UNDER_STRESSEBITDA margin on Total Revenue for Q1 FY27 was 20.1%, down from 22.7% in Q1 FY26 and up from 19.9% in Q4 FY26.
PAT
UNDER_STRESSPAT for Q1 FY27 was 374 Million, down 56.0% YoY but up 13.0% QoQ.
Management forward view
Focus on Strategic Levers for Growth
Management states that strategic levers such as sustained performance, driving for long-term growth, and adding 1300+ beds underpin the next phase of expansion.
Driving High-Quality, Affordable Care
The company aims to deliver high-quality care through affordable healthcare models, advanced transplant programs, and cutting-edge medical technology.
Regional Market Leadership Strategy
Management is focused on establishing a dominant presence in target geographies and accelerating new business growth.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Overall Occupancy Rate | 49.0% in Q1 FY27 | Improvement in occupancy rates across the expanded bed capacity, especially in newer units, to drive operational leverage. |
| EBITDA Margin Trend | 20.1% in Q1 FY27 (down from 22.7% YoY) | Stabilization and improvement in overall EBITDA margins, indicating successful integration and profitability ramp-up of new hospitals. |
| Profitability of New Units | Karnataka and Kompally units are EBITDA negative in Q1 FY27. | Timely turnaround of EBITDA-negative units to positive contribution, similar to Palakkad, Thane, and Guntur. |
| ARPOB and ARPP Growth | ARPOB up 9.7% YoY, ARPP up 6.8% YoY in Q1 FY27. | Sustained growth in ARPOB and ARPP, reflecting continued demand for high-value specialties and effective pricing strategies. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Show extracted source claims
margin outlookpartially deliveredquantified
Consolidated EBITDA margin is expected to continue at about 27% to 30%.
Timeframe: Next 2 or 3 yearsDirection: StableConfidence: Moderate to High
"we will continue to do about 27%, 30% kind of EBITDA margin over the next at least say, 2 or 3 years."
Outcome check: OPM moved from 21.0% to average 19.5% (-1.5 pp).
margin outlookpartially deliveredquantified
Core clusters like Telangana and Andhra Pradesh are expected to sustain an EBITDA margin of 25% to 30%.
Timeframe: OngoingDirection: StableConfidence: High
"ensuring that this margin trajectory remains there."
Outcome check: OPM moved from 21.0% to average 19.5% (-1.5 pp).
revenue outlookdeliveredquantified
Average revenue per occupied bed (ARPOB) is expected to increase from the current INR40,000-INR43,000 to almost INR50,000, driven by the scaling up of Maharashtra (Thane) and Bangalore markets.
Timeframe: Next 8 quartersDirection: UpwardConfidence: Moderate
"it can go up from the current INR40,000 to INR43,000 to almost INR50,000 over the next 8 quarters."
Outcome check: Revenue YoY averaged 32.1% across 2 later quarter(s).
Trust Score
70Healthy Trust · medium confidenceClaim-tested Trust
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Management has 100% delivered/partly-delivered outcomes on 3 checked claims. It ranks around the 63rd percentile of the scored universe and 50th percentile within Pharma. Main check: financial discipline is weak at 38/100.
Healthy Trust: 3/3 extracted management claims have outcome checks; 33% were fully delivered and 2 were partially delivered.
Computed 21 Oct 2026
management-trust-v1
43 extracted concalls · 3/3 claims matched
Score band
Healthy Trust
Generally investable credibility. Look for weak sub-scores before increasing position size.
Relative rank
63rd percentile
overall median 67 · Pharma: 50th pctile, median 70 · Large: 40th pctile, median 73
Evidence depth
Early sample
3/3 claims checked. Use as directional, not final.
Claim delivery
100% delivered or partly delivered
3/3 claims checked · No contradicted claim yet
How to read this Trust Score
Healthy Trust · medium confidenceWhat it measures
Reliability of management and financial delivery, using management claims matched with later outcomes.
Confidence
Useful directional evidence exists, but still verify the latest filings.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
70
acceptable · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
61
acceptable · leverage and solvency
Discipline
38
weak · capital discipline
Results
39
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸6 years of positive FCF.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸4 latest quarters had PAT decline worse than 25% YoY.
- ▸Promoter holding fell 1.6%.
- ▸Debt/equity is 1.89.
- ▸ROCE trend is -4.5%.
Continue researching Krishna Institute of Medical Sciences Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Sep - Anand Rathi Annual Flagship Conference G-200 Summit 2026 on September 22, 2026 in Mumbai.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 Sep - KIMS to meet institutional investors on 10 September 2026 at 2:30 p.m., hosted by Emkay Global.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements 10 Sep - KIMS signed 5-year renewable O&M agreement for 183-bed Trust Hospitals, Kakinada, earning 9% of net revenue.
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Jun - KIMS to attend Equirus Annual India Conference in Mumbai on August 14, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment 20 Aug - KIMS allotted 77,02,182 warrants to promoters, receiving Rs. 150 crore; conversion within 18 months.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Aug - Copy of Newspaper Publication towards intimation of notice of 24th Annual General Meeting of the Company.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Qualified Institutional Placement 19 Jun - Allotted 1.99 crore equity shares in QIP at ₹755, raising about ₹1,500 crore.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Jun
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Jun
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.